

Umberto Basso

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4825404/publications.pdf>

Version: 2024-02-01

209
papers

12,194
citations

61984

43
h-index

28297

105
g-index

212
all docs

212
docs citations

212
times ranked

14961
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunotherapy and Sonpavde score validation in advanced upper tract urothelial carcinoma: a retrospective study by the Italian Network for Research in Urologic-Oncology (Meet-URO group). <i>Immunotherapy</i> , 2022, 14, 107-114.	2.0	4
2	Immune checkpoint inhibitors rechallenge in urological tumors: An extensive review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 170, 103579.	4.4	10
3	Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210795.	3.2	10
4	Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors. <i>European Urology Focus</i> , 2022, 8, 1696-1702.	3.1	17
5	The Role of Fast and Deep PSA Response in Castration-sensitive Prostate Cancer. <i>Anticancer Research</i> , 2022, 42, 165-172.	1.1	4
6	Patterns of Disease Progression and Outcome of Patients With Testicular Seminoma Who Relapse After Adjuvant or Curative Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 825-832.	0.8	2
7	Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study. <i>Journal of Personalized Medicine</i> , 2022, 12, 727.	2.5	3
8	Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study. <i>Cancers</i> , 2022, 14, 2293.	3.7	4
9	Simultaneous Care in Oncology: A 7-Year Experience at ESMO Designated Centre at Veneto Institute of Oncology, Italy. <i>Cancers</i> , 2022, 14, 2568.	3.7	6
10	Real-World Treatment with Nivolumab or Cabozantinib for Metastatic Renal Cell Carcinoma (mRCC) in the Veneto Region of Italy: Results of AMOUR Study. <i>Targeted Oncology</i> , 2022, 17, 467-474.	3.6	3
11	To Transplant or Not to Transplant During the SARS-CoV-2 Pandemic? That Is the Question. <i>Oncologist</i> , 2021, 26, e336-e337.	3.7	2
12	Comprehensive geriatric assessment is an independent prognostic factor in older patients with metastatic renal cell cancer treated with first-line Sunitinib or Pazopanib: a single center experience. <i>Journal of Geriatric Oncology</i> , 2021, 12, 290-297.	1.0	11
13	Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study). <i>Clinical Medicine Insights: Oncology</i> , 2021, 15, 117955492110216.	1.3	12
14	Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2021, 384, 829-841.	27.0	961
15	Prognostic Stratification of Metastatic Prostate Cancer Patients Treated With Abiraterone and Enzalutamide Through an Integrated Analysis of Circulating Free microRNAs and Clinical Parameters. <i>Frontiers in Oncology</i> , 2021, 11, 626104.	2.8	6
16	Prognostic Role of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma: A Large, Multicenter, Prospective Trial. <i>Oncologist</i> , 2021, 26, 740-750.	3.7	19
17	Association of body surface area with fat mass, free fat mass and total weight in healthy individuals, and implications for the dosage of cytotoxic drugs. <i>Clinical Nutrition ESPEN</i> , 2021, 43, 471-477.	1.2	2
18	Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study. <i>Targeted Oncology</i> , 2021, 16, 625-632.	3.6	6

#	ARTICLE	IF	CITATIONS
19	Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?. <i>Diagnostics</i> , 2021, 11, 138.	2.6	13
20	Fatal hyperprogression induced by nivolumab in metastatic renal cell carcinoma with sarcomatoid features: a case report. <i>Anti-Cancer Drugs</i> , 2021, 32, 222-225.	1.4	3
21	An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the "Pamerit"™ study. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 484-491.	1.3	1
22	Prognostic Value of Thyroid Hormone Ratio in Patients With Advanced Metastatic Renal Cell Carcinoma: Results From the Threefour Study (Meet-URO 14). <i>Frontiers in Oncology</i> , 2021, 11, 787835.	2.8	9
23	First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series. <i>World Journal of Clinical Oncology</i> , 2021, 12, 1037-1046.	2.3	2
24	The Role of Radiolabeled Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for the Evaluation of Renal Cancer. <i>European Urology Focus</i> , 2020, 6, 146-150.	3.1	25
25	Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors. <i>Cancers</i> , 2020, 12, 84.	3.7	22
26	Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis. <i>Targeted Oncology</i> , 2020, 15, 495-501.	3.6	28
27	Management of Germ Cell Tumors During the Outbreak of the Novel Coronavirus Disease-19 Pandemic: A Survey of International Expertise Centers. <i>Oncologist</i> , 2020, 25, e1509-e1515.	3.7	10
28	A simple method for detecting oncofetal chondroitin sulfate glycosaminoglycans in bladder cancer urine. <i>Cell Death Discovery</i> , 2020, 6, 65.	4.7	5
29	Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 477-488.	1.9	15
30	Adherence to abiraterone or enzalutamide in elderly metastatic castration-resistant prostate cancer. <i>Supportive Care in Cancer</i> , 2020, 28, 4687-4695.	2.2	16
31	Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme. <i>BJU International</i> , 2019, 123, 98-105.	2.5	70
32	Immunotherapy in Dialysis-Dependent Cancer Patients: Our Experience in Patients With Metastatic Renal Cell Carcinoma and a Review of the Literature. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e903-e908.	1.9	30
33	Trabectedin Drug Holiday and Rechallenge in Soft Tissue Sarcomas: Report of 4 Cases and Literature Review. <i>Frontiers in Oncology</i> , 2019, 9, 553.	2.8	4
34	Immunotherapy and urothelial carcinoma: An overview and future perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 143, 46-55.	4.4	20
35	Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results. <i>Journal of Clinical Oncology</i> , 2019, 37, 1608-1616.	1.6	185
36	Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2019, 15, 1115-1123.	2.4	9

#	ARTICLE	IF	CITATIONS
37	Recommendations for surveillance and follow-up of men with testicular germ cell tumors: a multidisciplinary consensus conference by the Italian Germ cell cancer Group and the Associazione Italiana di Oncologia Medica. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 137, 154-164.	4.4	5
38	Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab. <i>Clinical Cancer Research</i> , 2019, 25, 3839-3846.	7.0	147
39	Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591989028.	3.2	74
40	Results From a Large, Multicenter, Retrospective Analysis On Radium223 Use in Metastatic Castration-resistant Prostate Cancer (mCRPC) in the Triveneto Italian Region. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e187-e194.	1.9	14
41	A New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated With First-Line Exemestane: Results From a Prospective Study. <i>Clinical Breast Cancer</i> , 2019, 19, 137-145.e4.	2.4	9
42	Oligometastatic recurrent prostate cancer detects by fluorine-18-choline positron emission tomography/computed tomography in patients with prostate-specific antigen levels of up to 5â€%ng/ml. <i>Nuclear Medicine Communications</i> , 2018, 39, 260-267.	1.1	5
43	Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2018, 378, 1277-1290.	27.0	3,334
44	International phase IV validation study of an EORTC quality of life questionnaire for testicular cancer patients: the EORTC QLQ-TC26. <i>BMC Cancer</i> , 2018, 18, 1104.	2.6	15
45	Autophagic Gene Polymorphisms in Liquid Biopsies and Outcome of Patients with Metastatic Clear Cell Renal Cell Carcinoma. <i>Anticancer Research</i> , 2018, 38, 5773-5782.	1.1	17
46	Enzalutamide after chemotherapy in advanced castration-resistant prostate cancer: the Italian Named Patient Program. <i>Future Oncology</i> , 2018, 14, 2691-2699.	2.4	3
47	Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or PoorÂPrognosis?. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 355-359.e1.	1.9	31
48	Toward a real liquid biopsy in metastatic breast and prostate cancer: Diagnostic LeukApheresis increases CTC yields in a European prospective multicenter study (CTCTrap). <i>International Journal of Cancer</i> , 2018, 143, 2584-2591.	5.1	68
49	Disease-specific and general health-related quality of life in newly diagnosed prostate cancer patients: the Pros-IT CNR study. <i>Health and Quality of Life Outcomes</i> , 2018, 16, 122.	2.4	24
50	Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database. <i>European Urology Oncology</i> , 2018, 1, 467-475.	5.4	25
51	Association of clinical progression at initiation of a life-extending therapy (LET) in metastatic castration-resistant prostate cancer (mCRPC) with poor prognosis: Results of the CATS database.. <i>Journal of Clinical Oncology</i> , 2018, 36, e17007-e17007.	1.6	1
52	Prognostic and predictive role of CTCs and AR-V7+ CTCs expression in metastatic castrate resistant prostate cancer (mCRPC): A feasibility study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 367-367.	1.6	1
53	Fluorocholine PET/CT predicts skeletal progression, skeletal event and cancer specific survival in patients with biochemical relapse for prostate cancer. <i>Clinical Imaging</i> , 2017, 43, 110-116.	1.5	3
54	Pros-IT CNR: an Italian prostate cancer monitoring project. <i>Ageing Clinical and Experimental Research</i> , 2017, 29, 165-172.	2.9	26

#	ARTICLE	IF	CITATIONS
55	Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-ST5 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. <i>Lancet Oncology</i> , 2017, 18, 812-822.	10.7	370
56	Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. <i>New England Journal of Medicine</i> , 2017, 377, 352-360.	27.0	1,588
57	Isolated limb perfusion for the management limb threatening soft tissue sarcomas: The role of histological type on clinical outcomes. <i>European Journal of Surgical Oncology</i> , 2017, 43, 401-406.	1.0	10
58	Cost of illness of urothelial bladder cancer in Italy. <i>ClinicoEconomics and Outcomes Research</i> , 2017, Volume 9, 433-442.	1.9	15
59	Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the Targeted Therapy Era: Results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC). <i>Kidney Cancer</i> , 2017, 1, 41-47.	0.4	13
60	Outcome of Men With Relapse After Adjuvant Carboplatin for Clinical Stage I Seminoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 194-200.	1.6	41
61	Abstract 1723: Diagnostic leukapheresis results in a significant increase in CTC yield in metastatic breast and prostate cancer. , 2017, , .		1
62	Prognostic role of circulating tumor cells-CTCs in metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4568-4568.	1.6	4
63	Safety and efficacy of nivolumab for metastatic renal cell carcinoma (mRCC): Real world data from an Italian expanded access program (EAP).. <i>Journal of Clinical Oncology</i> , 2017, 35, 4577-4577.	1.6	3
64	Outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequence in post-docetaxel (DOC) setting: Final analysis from a multicenter Italian study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5030-5030.	1.6	5
65	Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. <i>Oncotarget</i> , 2016, 7, 54564-54571.	1.8	116
66	Prognostic Value of Plasma and Urine Glycosaminoglycan Scores in Clear Cell Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2016, 6, 253.	2.8	22
67	Long-term response to first-line trabectedin in an elderly female patient with a metastatic leiomyosarcoma unfit for anthracycline. <i>Anti-Cancer Drugs</i> , 2016, 27, 264-267.	1.4	9
68	Prevention of Hepatitis B Virus Reactivation With Lamivudine in a Patient With Advanced Renal Cell Carcinoma Treated With Everolimus. <i>American Journal of Therapeutics</i> , 2016, 23, e300-e303.	0.9	7
69	Epicure: a European epidemiological study of patients with an advanced or metastatic Urothelial Carcinoma (UC) having progressed to a platinum-based chemotherapy. <i>BMC Cancer</i> , 2016, 16, 752.	2.6	6
70	Sirolimus in Advanced Epithelioid Hemangioendothelioma: A Retrospective Case-Series Analysis from the Italian Rare Cancer Network Database. <i>Annals of Surgical Oncology</i> , 2016, 23, 2735-2744.	1.5	56
71	Outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequence in post-docetaxel (DOC) setting. An updated analysis from a multicenter Italian study. <i>Annals of Oncology</i> , 2016, 27, vi252.	1.2	2
72	A Solitary Metastasis for a Malignant Schwannoma in the Gallbladder Detected by 18F-FDG PET/CT. <i>Clinical Nuclear Medicine</i> , 2016, 41, 666-667.	1.3	5

#	ARTICLE	IF	CITATIONS
73	Glycosaminoglycan Profiling in Patientsâ€™ Plasma and Urine Predicts the Occurrence of Metastatic Clear Cell Renal Cell Carcinoma. <i>Cell Reports</i> , 2016, 15, 1822-1836.	6.4	55
74	Development of an oncological-multidimensional prognostic index (Onco-MPI) for mortality prediction in older cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1069-1077.	2.5	52
75	Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer. <i>Future Oncology</i> , 2016, 12, 493-502.	2.4	8
76	Role of dose exposure and inflammatory status in a single center, real-world analysis of sunitinib in patients with metastatic renal cell carcinoma. <i>Future Oncology</i> , 2016, 12, 909-919.	2.4	4
77	Adjuvant Carboplatin Treatment in 115 Patients With Stage I Seminoma: Retrospective Multicenter Survey. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e161-e169.	1.9	16
78	More on sunitinib 2 weeks on/1 week off schedule: the Rainbow analysis. <i>Annals of Oncology</i> , 2016, 27, 202-203.	1.2	1
79	Adjuvant chemotherapy for soft tissue sarcomas: a 10-year mono-institutional experience. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 679-685.	2.5	7
80	Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 48-55.	1.9	14
81	Outcomes of metastatic chromophobe renal cell carcinoma (chrRCC) in the targeted therapy era: Results from the International Metastatic Renal Cell Cancer Database Consortium.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4570-4570.	1.6	1
82	Sequential administration of new agents (NAs) after docetaxel (DOC) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts): Impact of disease control (DC) duration in second line on the subsequent line outcomes.. <i>Journal of Clinical Oncology</i> , 2016, 34, 210-210.	1.6	0
83	Activity of new agents (NAs) as third-line treatment in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) after a long-term disease control (LTDC) with abiraterone acetate (AA) or enzalutamide (ENZ) post docetaxel (DOC): Preliminary results from a multicenter Italian study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 325-325.	1.6	0
84	Systemic immune-inflammation index to predict the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.. <i>Journal of Clinical Oncology</i> , 2016, 34, 547-547.	1.6	1
85	Do pathological parameters of primary tumor correlate with overall survival (OS) of metastatic clear-cell renal cell carcinoma (ccRCC)?. <i>Journal of Clinical Oncology</i> , 2016, 34, 549-549.	1.6	0
86	Chemotherapy (CT) for advanced soft tissue sarcoma (STS) in older patients (pts): Toxicity and outcomes in a single center experience.. <i>Journal of Clinical Oncology</i> , 2016, 34, e21527-e21527.	1.6	0
87	2601 Outcome of relapses after adjuvant carboplatin in clinical stage I seminoma. <i>European Journal of Cancer</i> , 2015, 51, S511-S512.	2.8	1
88	Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the Italian Named Patient Programme. <i>BJU International</i> , 2015, 115, 764-771.	2.5	17
89	2627 Characteristics and treatments patterns of patients with an advanced or metastatic urothelial carcinoma (UC) after failure of a platinum-based chemotherapy (CT): Results of the European observational study EPICURE. <i>European Journal of Cancer</i> , 2015, 51, S521.	2.8	0
90	OECl Accreditation at Veneto Institute of Oncology IOV - IRCCS, General Framework and Multidisciplinary Approach. <i>Tumori</i> , 2015, 101, S38-S41.	1.1	1

#	ARTICLE	IF	CITATIONS
91	Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. <i>European Urology</i> , 2015, 68, 147-153.	1.9	73
92	Surgical Resection Does Not Improve Survival in Patients with Renal Metastases to the Pancreas in the Era of Tyrosine Kinase Inhibitors. <i>Annals of Surgical Oncology</i> , 2015, 22, 2094-2100.	1.5	72
93	Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients. <i>Future Oncology</i> , 2015, 11, 965-973.	2.4	10
94	Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy. <i>Targeted Oncology</i> , 2015, 10, 517-522.	3.6	49
95	Safety and Efficacy of Sunitinib in Patients from Italy with Metastatic Renal Cell Carcinoma: Final Results from an Expanded-Access Trial. <i>Oncology</i> , 2015, 88, 273-280.	1.9	24
96	Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients. <i>Future Oncology</i> , 2015, 11, 2881-2891.	2.4	12
97	Good survival outcome of metastatic SDH-deficient gastrointestinal stromal tumors harboring SDHA mutations. <i>Genetics in Medicine</i> , 2015, 17, 391-395.	2.4	41
98	Sunitinib, Pazopanib or Sorafenib for the Treatment of Patients with Late Relapsing Metastatic Renal Cell Carcinoma. <i>Journal of Urology</i> , 2015, 193, 41-47.	0.4	58
99	First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippel-Lindau (VHL) disease: clinical outcome and patterns of radiological response. <i>Familial Cancer</i> , 2015, 14, 309-316.	1.9	21
100	Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations. <i>Annals of Oncology</i> , 2015, 26, 288-300.	1.2	607
101	Activity of new agents (NAs) as third-line treatment in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) showing a primary resistance (PRes) to NAs-based second line therapy after docetaxel (DOC): Preliminary results from a multicenter Italian study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 216-216.	1.6	0
102	Primary resistance to abiraterone acetate (AA) after docetaxel treatment in metastatic castration-resistant prostate cancer (mCRPC): A multicenter retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2015, 33, 206-206.	1.6	0
103	Visceral disease site to predict clinical outcome of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA): Results of the Italian compassionate use named patient program (NPP).. <i>Journal of Clinical Oncology</i> , 2015, 33, e16045-e16045.	1.6	0
104	Systemic immune-inflammation index (SII) as prognostic/predictive factor in patients (pts) with metastatic renal cell cancer (mRCC) treated with sunitinib.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15595-e15595.	1.6	0
105	Non-pegylated liposomal doxorubicin plus ifosfamide in metastatic soft tissue sarcoma: results from a phase-II trial. <i>Anticancer Research</i> , 2015, 35, 543-7.	1.1	14
106	Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2014, 10, 975-983.	2.4	43
107	Response to trabectedin in a patient with advanced synovial sarcoma with lung metastases. <i>Anti-Cancer Drugs</i> , 2014, 25, 1227-1230.	1.4	6
108	Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer. <i>Journal of Geriatric Oncology</i> , 2014, 5, 156-163.	1.0	22

#	ARTICLE	IF	CITATIONS
109	Standard vs Adapted Sunitinib Regimen in Elderly Patients With Metastatic Renal Cell Cancer: Results From a Large Retrospective Analysis. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 182-189.	1.9	23
110	Neoadjuvant sirolimus for a large hepatic perivascular epithelioid cell tumor (PEComa). <i>World Journal of Surgical Oncology</i> , 2014, 12, 46.	1.9	33
111	Is It Possible That One Patient May Again Experience a Response to Abiraterone Acetate Withdrawal During an Abiraterone Acetate Rechallenge?. <i>European Urology</i> , 2014, 66, 179-180.	1.9	5
112	Analysis of all subunits, SDHA, SDHB, SDHC, SDHD, of the succinate dehydrogenase complex in KIT/PDGFR α wild-type GIST. <i>European Journal of Human Genetics</i> , 2014, 22, 32-39.	2.8	90
113	Activity of subsequent new drugs (NDs) in post-docetaxel (DOC) failure for metastatic castration-resistant prostate cancer (mCRPC) patients (pts): A multicenter Italian experience.. <i>Journal of Clinical Oncology</i> , 2014, 32, 5089-5089.	1.6	6
114	Safety and clinical outcome of a cohort of patients (pts) with castration resistant prostate cancer (CRPC) treated with abiraterone acetate (AA) in a named patient program (NPP): Updated results of a retrospective study from an Italian cooperative group.. <i>Journal of Clinical Oncology</i> , 2014, 32, 253-253.	1.6	1
115	Clinical outcomes of patients (pts) age 80 or older treated with docetaxel (DOC) as first-line chemotherapy for castration-resistant prostate cancer (CRPC): Results of an Italian multicenter retrospective study (DELPHI study).. <i>Journal of Clinical Oncology</i> , 2014, 32, 92-92.	1.6	2
116	Differences in terms of progression-free survival (PFS) and overall survival (OS) in patients treated with first-line sorafenib, sunitinib, and pazopanib for late relapsing (>5 years) renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 421-421.	1.6	0
117	Dose calculation and tolerability of adjuvant AUC 7 carboplatin in 100 patients with stage I seminoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 374-374.	1.6	0
118	A proposed new model for prognostic stratification of poor-risk patients with metastatic renal cell carcinoma (mRCC) in the era of targeted therapy.. <i>Journal of Clinical Oncology</i> , 2014, 32, e15588-e15588.	1.6	0
119	Prognostic factors in patients with pancreatic metastases from renal cell carcinoma (PM-RCC): Room for thinking about the role of surgery?. <i>Journal of Clinical Oncology</i> , 2014, 32, e15563-e15563.	1.6	0
120	Soft tissue limb and trunk sarcomas: diagnosis, treatment and follow-up. <i>Anticancer Research</i> , 2014, 34, 5251-62.	1.1	12
121	Cross-cultural development of an EORTC questionnaire to assess health-related quality of life in patients with testicular cancer: the EORTC QLQ-TC26. <i>Quality of Life Research</i> , 2013, 22, 369-378.	3.1	28
122	Bi-weekly liposomal doxorubicin for advanced breast cancer in elderly women (â‰¥70years). <i>Journal of Geriatric Oncology</i> , 2013, 4, 340-345.	1.0	18
123	Adjuvant and Neoadjuvant Chemotherapy for Soft Tissue Sarcomas. <i>Current Medicinal Chemistry</i> , 2013, 20, 613-620.	2.4	10
124	Metastatic malignant soft tissue myoepithelioma: a case report showing complete response after locoregional and systemic therapy. <i>Journal of Surgical Case Reports</i> , 2013, 2013, rjt109-rjt109.	0.4	6
125	Targeted Approaches to Triple-Negative Breast Cancer: Current Practice and Future Directions. <i>Current Medicinal Chemistry</i> , 2013, 20, 605-612.	2.4	18
126	Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trial. <i>Annals of Oncology</i> , 2013, 24, 2967-2971.	1.2	22

#	ARTICLE	IF	CITATIONS
127	Adherence to treatment guidelines for primary sarcomas affects patient survival: a side study of the European CONnective Tissue Cancer NETwork (CONTICANET). <i>Annals of Oncology</i> , 2013, 24, 1685-1691.	1.2	61
128	Phase II prospective study with sorafenib in advanced soft tissue sarcomas after anthracycline-based therapy. <i>Annals of Oncology</i> , 2013, 24, 1093-1098.	1.2	48
129	Treatment of Estrogen Receptor-Positive Breast Cancer. <i>Current Medicinal Chemistry</i> , 2013, 20, 596-604.	2.4	213
130	Safety and activity of sunitinib in elderly patients (≥70 years) with metastatic renal cell carcinoma: a multicenter study. <i>Annals of Oncology</i> , 2013, 24, 336-342.	1.2	42
131	Retaining the long-survive capacity of Circulating Tumor Cells (CTCs) followed by xeno-transplantation: not only from metastatic cancer of the breast but also of prostate cancer patients. <i>Oncoscience</i> , 2013, 1, 49-56.	2.2	52
132	Which data for cabazitaxel (Cbz) from the real world? The safety experience from the Italian centres participating in the Expanded Access Programme (EAP).. <i>Journal of Clinical Oncology</i> , 2013, 31, 189-189.	1.6	0
133	Impact of intermittent (I) first-line docetaxel (D)-based chemotherapy on quality of life (QL) of patients (pts) with castration-resistant prostate cancer (CRPC): Results of a phase II randomized trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, 90-90.	1.6	0
134	Clinical outcomes and toxicity of estramustine phosphate (EP) addition to docetaxel (D) as first-line therapy for castration-resistant prostate cancer (CRPC): A cumulative analysis on 243 patients (pts) from two randomized phase II trials.. <i>Journal of Clinical Oncology</i> , 2013, 31, 208-208.	1.6	0
135	Adjuvant! Online or comprehensive geriatric assessment for women over 70 years with primary breast cancer?. <i>British Journal of Cancer</i> , 2012, 106, 1247-1247.	6.4	0
136	Dynamic changes of live/apoptotic circulating tumour cells as predictive marker of response to Sunitinib in metastatic renal cancer. <i>British Journal of Cancer</i> , 2012, 107, 1286-1294.	6.4	55
137	Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer. <i>Journal of Bone and Mineral Metabolism</i> , 2012, 30, 461-467.	2.7	10
138	Preliminary results of a factorial phase II randomized trial of continuous (C) or intermittent (I) docetaxel (DOC) with or without estramustine (E) as first-line treatment for castration-resistant prostate cancer (CRPC) (HOPLITE trial).. <i>Journal of Clinical Oncology</i> , 2012, 30, 220-220.	1.6	0
139	Sunitinib as first-line therapy in elderly patients (age 70 and older) with metastatic renal cell cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 411-411.	1.6	1
140	Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA). <i>Lung Cancer</i> , 2011, 73, 78-88.	2.0	4
141	Endocrine Therapy of Breast Cancer. <i>Current Medicinal Chemistry</i> , 2011, 18, 513-522.	2.4	140
142	Cancer in the elderly. <i>Internal and Emergency Medicine</i> , 2011, 6, 115-118.	2.0	5
143	Malignant Hypercalcemia. <i>Current Medicinal Chemistry</i> , 2011, 18, 3462-3467.	2.4	33
144	Axillary node sampling in conjunction with sentinel node biopsy in patients with breast cancer. A prospective preliminary study. <i>Anticancer Research</i> , 2011, 31, 693-7.	1.1	7

#	ARTICLE	IF	CITATIONS
145	Genotype-Driven Phase I Study of Irinotecan Administered in Combination With Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 866-871.	1.6	156
146	Prognostic Factors in Patients With Metastatic Germ Cell Tumors Who Experienced Treatment Failure With Cisplatin-Based First-Line Chemotherapy. <i>Journal of Clinical Oncology</i> , 2010, 28, 4906-4911.	1.6	267
147	M30 Neoepitope Expression in Epithelial Cancer: Quantification of Apoptosis in Circulating Tumor Cells by CellSearch Analysis. <i>Clinical Cancer Research</i> , 2010, 16, 5233-5243.	7.0	124
148	Estrogen therapy and risk of breast cancer in postmenopausal women. <i>Menopause</i> , 2010, 17, 524-528.	2.0	9
149	Sorafenib is active on lung metastases from synovial sarcoma. <i>Annals of Oncology</i> , 2009, 20, 386-387.	1.2	14
150	Oligonucleotide Probe Array for p53 Gene Alteration Analysis in DNA from Formalin-Fixed Paraffin-Embedded Breast Cancer Tissues. <i>Annals of the New York Academy of Sciences</i> , 2009, 1175, 89-92.	3.8	2
151	Management of primary and advanced breast cancer in older unfit patients (medical treatment). <i>Cancer Treatment Reviews</i> , 2009, 35, 503-508.	7.7	41
152	Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma. <i>Bone</i> , 2009, 44, 173-175.	2.9	95
153	Gastrointestinal stromal tumors: report of an audit and review of the literature. <i>European Journal of Cancer Prevention</i> , 2009, 18, 106-116.	1.3	45
154	Cancer-induced hypercalcemia. <i>Anticancer Research</i> , 2009, 29, 1551-5.	1.1	74
155	FNA cytology and frozen section examination in patients with follicular lesions of the thyroid gland. <i>Anticancer Research</i> , 2009, 29, 5255-7.	1.1	35
156	Management of Frail and Not-Frail elderly cancer patients in a hospital-based geriatric oncology program. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 66, 163-170.	4.4	59
157	Vulnerable and frail elderly: An approach to the management of the main tumour types. <i>European Journal of Cancer</i> , 2008, 44, 488-493.	2.8	17
158	Nutritional Habits and Body Mass Index in the Elderly Population: Can This Information Be Useful Before Planning Chemotherapy Administration in Older Cancer Patients?. <i>Nutrition and Cancer</i> , 2008, 60, 552-554.	2.0	0
159	Medical Treatment of Malignancy-Associated Hypercalcemia. <i>Current Medicinal Chemistry</i> , 2008, 15, 415-421.	2.4	51
160	Chemotherapy and Targeted Agents for Elderly Women with Advanced Breast Cancer. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2008, 3, 187-201.	1.6	17
161	Relationship between oral contraceptive therapy and estrogen receptor status in patients with breast cancer. <i>Anticancer Research</i> , 2008, 28, 491-3.	1.1	1
162	Neoadjuvant carboplatin and vinorelbine followed by chemoradiotherapy in locally advanced head and neck or oesophageal squamous cell carcinoma: a phase II study in elderly patients or patients with poor performance status. <i>Anticancer Research</i> , 2008, 28, 1383-8.	1.1	15

#	ARTICLE	IF	CITATIONS
163	Rectal cancer adjuvant chemotherapy: when is more useful?. <i>Anticancer Research</i> , 2008, 28, 1805-12.	1.1	0
164	Adjuvant treatment for elderly patients with colon cancer. An observational study. <i>Anticancer Research</i> , 2008, 28, 2513-8.	1.1	9
165	Neoadjuvant chemoradiotherapy with 5-fluorouracil by bolus. <i>Anticancer Research</i> , 2008, 28, 4095-100.	1.1	0
166	Role of neoadjuvant treatment in cT3N0M0 rectal cancer. <i>Anticancer Research</i> , 2008, 28, 4129-35.	1.1	0
167	Which benefit from adding gemcitabine to vinorelbine in elderly (≥70 years) women with metastatic breast cancer? Early interruption of a phase II study. <i>Annals of Oncology</i> , 2007, 18, 58-63.	1.2	19
168	Thyroid C-Cell Hyperplasia Shown by Combined In-111 Pentetreotide, Tc-99m Perchnetate, and Tc-99m MIBI Scintigraphy. <i>Clinical Nuclear Medicine</i> , 2007, 32, 378-379.	1.3	0
169	Oncological causes of frailty in older cancer patients. <i>European Journal of Cancer</i> , 2007, 43, 1230-1231.	2.8	16
170	Ifosfamide-Related Encephalopathy in Elderly Patients. <i>Drugs and Aging</i> , 2007, 24, 967-973.	2.7	32
171	Determining Therapeutic Approaches in the Elderly with Rectal Cancer. <i>Drugs and Aging</i> , 2007, 24, 781-790.	2.7	9
172	When Should Trastuzumab be Stopped after Achieving Complete Response in Her2-Positive Metastatic Breast Cancer Patients?. <i>Tumori</i> , 2007, 93, 491-492.	1.1	18
173	Primary rectal carcinoma in patients with stage IV resectable disease at diagnosis. <i>Anticancer Research</i> , 2007, 27, 1079-85.	1.1	5
174	Axillary lymph node metastases detection with 99mTc-sestamibi scintimammography in patients with breast cancer undergoing curative surgery. <i>Anticancer Research</i> , 2007, 27, 2949-52.	1.1	2
175	Overprotective Caregivers of Elderly Cancer Patients: A Case Report. <i>Tumori</i> , 2006, 92, 362-363.	1.1	0
176	Do older women with breast cancer benefit from adjuvant chemotherapy?. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 652-653.	4.3	2
177	Rectal cancer neoadjuvant treatment in elderly patients. <i>Anticancer Research</i> , 2006, 26, 3913-23.	1.1	24
178	Parathyroid cancer: etiology, clinical presentation and treatment. <i>Anticancer Research</i> , 2006, 26, 4803-7.	1.1	25
179	Vinorelbine and prednisone in frail elderly patients with intermediate-high grade non-Hodgkin's lymphomas. <i>Annals of Oncology</i> , 2005, 16, 1352-1358.	1.2	48
180	New standards in the chemotherapy of metastatic hormone-refractory prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2005, 5, 53-62.	2.4	5

#	ARTICLE	IF	CITATIONS
181	Adjuvant chemotherapy for elderly patients (≥70 years) with early high-risk breast cancer: a retrospective analysis of 260 patients. <i>Annals of Oncology</i> , 2005, 16, 1276-1282.	1.2	37
182	Treatment options for early breast cancer in elderly women. <i>Expert Review of Anticancer Therapy</i> , 2004, 4, 197-211.	2.4	12
183	Second-Line Chemotherapy With Irinotecan Plus Carmustine in Glioblastoma Recurrent or Progressive After First-Line Temozolomide Chemotherapy: A Phase II Study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). <i>Journal of Clinical Oncology</i> , 2004, 22, 4779-4786.	1.6	113
184	First-Line Chemotherapy With Cisplatin Plus Fractionated Temozolomide in Recurrent Glioblastoma Multiforme: A Phase II Study of the Gruppo Italiano Cooperativo di Neuro-Oncologia. <i>Journal of Clinical Oncology</i> , 2004, 22, 1598-1604.	1.6	97
185	Management of muscle-invasive bladder cancer in the elderly. <i>Expert Review of Anticancer Therapy</i> , 2004, 4, 1017-1035.	2.4	8
186	Multidimensional geriatric evaluation in elderly cancer patients: a practical approach. <i>European Journal of Cancer Care</i> , 2004, 13, 424-433.	1.5	52
187	A multicenter study of the prognosis and treatment of adult brain ependymal tumors. <i>Cancer</i> , 2004, 100, 1221-1229.	4.1	105
188	A prospective study on glioblastoma in the elderly. <i>Cancer</i> , 2003, 97, 657-662.	4.1	169
189	The treatment of adults with medulloblastoma: a prospective study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 57, 755-761.	0.8	82
190	Improved tolerability of chemotherapy in soft tissue sarcomas: old and new strategies. <i>Expert Review of Anticancer Therapy</i> , 2003, 3, 167-178.	2.4	3
191	Carboplatin and teniposide as third-line chemotherapy in patients with recurrent oligodendroglioma or oligoastrocytoma: a phase II study. <i>Annals of Oncology</i> , 2003, 14, 1727-1731.	1.2	38
192	Recommendations for the management of malignant gliomas in the elderly. <i>Expert Review of Anticancer Therapy</i> , 2003, 3, 643-654.	2.4	7
193	Medulloblastomas: do molecular and biologic markers indicate different prognoses and treatments?. <i>Expert Review of Anticancer Therapy</i> , 2003, 3, 615-620.	2.4	11
194	Controversies in the therapy of low-grade glioma: when and how to treat. <i>Expert Review of Anticancer Therapy</i> , 2002, 2, 529-536.	2.4	3
195	Is intra-arterial chemotherapy useful in high-grade gliomas?. <i>Expert Review of Anticancer Therapy</i> , 2002, 2, 507-519.	2.4	15
196	A multidrug combination designed for reversing resistance to BCNU in glioblastoma multiforme. <i>Neurology</i> , 2002, 58, 1759-1764.	1.1	27
197	Breast cancer risk in healthy and symptomatic women: results of a multivariate analysis. A case-control study. <i>Biomedicine and Pharmacotherapy</i> , 2002, 56, 416-420.	5.6	8
198	Diagnostic advances and new trends for the treatment of primary central nervous system lymphoma. <i>European Journal of Cancer</i> , 2002, 38, 1298-1312.	2.8	30

#	ARTICLE	IF	CITATIONS
199	Temozolomide in Glioblastoma Multiforme of the Elderly. <i>Tumori</i> , 2002, 88, S69-S70.	1.1	1
200	Temozolomide in Patients with Glioblastoma at Second Relapse after First Line Nitrosourea-Procarbazine Failure: A Phase II Study. <i>Oncology</i> , 2002, 63, 38-41.	1.9	55
201	Non-cytotoxic therapies for malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2002, 58, 57-69.	2.9	21
202	New Strategy Developments in Brain Tumor Therapy. <i>Current Pharmaceutical Design</i> , 2001, 7, 1553-80.	1.9	15
203	High-Dose Chemotherapy with Bone Marrow Rescue for High-Grade Gliomas in Adults. <i>Cancer Investigation</i> , 2001, 19, 41-48.	1.3	20
204	Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: A phase II study. <i>Annals of Oncology</i> , 2001, 12, 255-258.	1.2	77
205	Changing boundaries in the treatment of malignant gliomas. <i>Expert Review of Anticancer Therapy</i> , 2001, 1, 357-370.	2.4	9
206	Regulation of alveolar macrophage-T cell interactions during Th1-type sarcoid inflammatory process. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 1999, 277, L240-L250.	2.9	35
207	Telomerase activity in chronic lymphoproliferative disorders of B-cell lineage. <i>British Journal of Haematology</i> , 1999, 106, 662-668.	2.5	50
208	CD8 T-Cell Infiltration in Extravascular Tissues of Patients With Human Immunodeficiency Virus Infection. Interleukin-15 Upmodulates Costimulatory Pathways Involved in the Antigen-Presenting Cellsâ€™T-Cell Interaction. <i>Blood</i> , 1999, 93, 1277-1286.	1.4	11
209	Cells and molecules involved in the development of sarcoid granuloma. <i>Journal of Clinical Immunology</i> , 1998, 18, 184-192.	3.8	44